Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Accured Expenses (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Change in Accured Expenses for 8 consecutive years, with -$546000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 111.72% to -$546000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$940000.0, a 117.6% decrease, with the full-year FY2024 number at $202000.0, changed N/A from a year prior.
  • Change in Accured Expenses was -$546000.0 for Q3 2025 at Whitehawk Therapeutics, up from -$1.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.9 million in Q4 2023 to a low of -$5.1 million in Q2 2023.
  • A 5-year average of $609111.1 and a median of $803000.0 in 2021 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 571.63% in 2022; the steepest drop was 797.47% in 2022.
  • Whitehawk Therapeutics' Change in Accured Expenses stood at $3.4 million in 2021, then crashed by 62.01% to $1.3 million in 2022, then surged by 279.66% to $4.9 million in 2023, then tumbled by 103.88% to -$192000.0 in 2024, then plummeted by 184.38% to -$546000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Change in Accured Expenses are -$546000.0 (Q3 2025), -$1.2 million (Q2 2025), and $975000.0 (Q1 2025).